Intellia Therapeutics (NTLA) Enterprise Value (2016 - 2025)
Intellia Therapeutics (NTLA) has disclosed Enterprise Value for 11 consecutive years, with -$449.9 million as the latest value for Q4 2025.
- On a quarterly basis, Enterprise Value rose 25.21% to -$449.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$449.9 million, a 25.21% increase, with the full-year FY2025 number at -$449.9 million, up 25.21% from a year prior.
- Enterprise Value was -$449.9 million for Q4 2025 at Intellia Therapeutics, up from -$511.0 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$449.9 million in Q4 2025 to a low of -$1.2 billion in Q4 2022.
- A 5-year average of -$734.4 million and a median of -$771.0 million in 2021 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: tumbled 133.38% in 2021, then skyrocketed 36.34% in 2025.
- Intellia Therapeutics' Enterprise Value stood at -$750.8 million in 2021, then crashed by 58.85% to -$1.2 billion in 2022, then rose by 23.51% to -$912.2 million in 2023, then soared by 34.06% to -$601.5 million in 2024, then grew by 25.21% to -$449.9 million in 2025.
- Per Business Quant, the three most recent readings for NTLA's Enterprise Value are -$449.9 million (Q4 2025), -$511.0 million (Q3 2025), and -$459.7 million (Q2 2025).